Abstract:Purpose/Objective(s)The ability to quantify the tumor subvolume with unfavorable functional/biological imaging properties within the heterogeneous tumor has recently been reported to improve the early prediction of tumor control and survival in cervix cancer. However, the optimal threshold of the imaging biomarker's values to functionally differentiate unfavorable vs. favorable tumor voxels have not been determined at different treatment time points. This study applied dynamic contrast-enhanced (DCE) MRI to classify at-risk tumor voxels, likely contributing to treatment failure, with various DCE threshold values and correlate the at-risk tumor subvolume component within the heterogeneous tumor with clinical therapy outcome for early outcome prediction.Materials/MethodsIn 104 patients with Stage IB2-IVA cervix cancer, DCE-MRI scans were obtained at three different treatment time points: before and during treatment at 2 to 2.5 weeks (20 – 25 Gy) and at 4 to 5 weeks (40 – 50 Gy). For each tumor voxel, the plateau signal intensity (SI) was derived from the dynamic time-SI curve of the DCE-MRI. For each imaging time point, SI threshold values ranging from 1 to 3 were explored to define at-risk tumor voxels. The component of at-risk tumor voxels within the entire tumor voxel population was correlated with clinical outcome. The optimal SI thresholds to differentiate local control vs. failure and disease-specific survival vs. cancer death were determined for each imaging time point using ROC and Mann-Whitney analysis. Mean follow-up was 6.8 years.ResultsThe optimal SI threshold values, before treatment and at 2 to 2.5 and 4 to 5 weeks into treatment, are summarized in Table 1 (rows 3, 4, and 6). These optimal thresholds showed minor differences among different time points throughout the radiation therapy course. When a uniform of SI = 2.1 was applied to the different time points to classify at-risk voxels, the differentiation of favorable vs. unfavorable outcome continued to be highly significant for all three MRI imaging time points (row 7).ConclusionsTableOptimal SI threshold value to classify unfavorable tumor voxels at different imaging timesLocal tumor controlDisease-specific survivalMRI time pointPre-RT20–25 Gy40–50 GyPre-RT20–25 Gy40–50 GyMaximum area under ROC curve (AUC)0.660.780.800.660.710.69First derivative of AUC000000Optimal SI2.12.02.11.82.11.8p value with time-specific SI0.038.0E−53.7E−50.0090.0010.003p value with same SI = 2.1 for all times0.031.2E−43.7E−50.0150.0010.008 Open table in a new tab Purpose/Objective(s)The ability to quantify the tumor subvolume with unfavorable functional/biological imaging properties within the heterogeneous tumor has recently been reported to improve the early prediction of tumor control and survival in cervix cancer. However, the optimal threshold of the imaging biomarker's values to functionally differentiate unfavorable vs. favorable tumor voxels have not been determined at different treatment time points. This study applied dynamic contrast-enhanced (DCE) MRI to classify at-risk tumor voxels, likely contributing to treatment failure, with various DCE threshold values and correlate the at-risk tumor subvolume component within the heterogeneous tumor with clinical therapy outcome for early outcome prediction. The ability to quantify the tumor subvolume with unfavorable functional/biological imaging properties within the heterogeneous tumor has recently been reported to improve the early prediction of tumor control and survival in cervix cancer. However, the optimal threshold of the imaging biomarker's values to functionally differentiate unfavorable vs. favorable tumor voxels have not been determined at different treatment time points. This study applied dynamic contrast-enhanced (DCE) MRI to classify at-risk tumor voxels, likely contributing to treatment failure, with various DCE threshold values and correlate the at-risk tumor subvolume component within the heterogeneous tumor with clinical therapy outcome for early outcome prediction. Materials/MethodsIn 104 patients with Stage IB2-IVA cervix cancer, DCE-MRI scans were obtained at three different treatment time points: before and during treatment at 2 to 2.5 weeks (20 – 25 Gy) and at 4 to 5 weeks (40 – 50 Gy). For each tumor voxel, the plateau signal intensity (SI) was derived from the dynamic time-SI curve of the DCE-MRI. For each imaging time point, SI threshold values ranging from 1 to 3 were explored to define at-risk tumor voxels. The component of at-risk tumor voxels within the entire tumor voxel population was correlated with clinical outcome. The optimal SI thresholds to differentiate local control vs. failure and disease-specific survival vs. cancer death were determined for each imaging time point using ROC and Mann-Whitney analysis. Mean follow-up was 6.8 years. In 104 patients with Stage IB2-IVA cervix cancer, DCE-MRI scans were obtained at three different treatment time points: before and during treatment at 2 to 2.5 weeks (20 – 25 Gy) and at 4 to 5 weeks (40 – 50 Gy). For each tumor voxel, the plateau signal intensity (SI) was derived from the dynamic time-SI curve of the DCE-MRI. For each imaging time point, SI threshold values ranging from 1 to 3 were explored to define at-risk tumor voxels. The component of at-risk tumor voxels within the entire tumor voxel population was correlated with clinical outcome. The optimal SI thresholds to differentiate local control vs. failure and disease-specific survival vs. cancer death were determined for each imaging time point using ROC and Mann-Whitney analysis. Mean follow-up was 6.8 years. ResultsThe optimal SI threshold values, before treatment and at 2 to 2.5 and 4 to 5 weeks into treatment, are summarized in Table 1 (rows 3, 4, and 6). These optimal thresholds showed minor differences among different time points throughout the radiation therapy course. When a uniform of SI = 2.1 was applied to the different time points to classify at-risk voxels, the differentiation of favorable vs. unfavorable outcome continued to be highly significant for all three MRI imaging time points (row 7). The optimal SI threshold values, before treatment and at 2 to 2.5 and 4 to 5 weeks into treatment, are summarized in Table 1 (rows 3, 4, and 6). These optimal thresholds showed minor differences among different time points throughout the radiation therapy course. When a uniform of SI = 2.1 was applied to the different time points to classify at-risk voxels, the differentiation of favorable vs. unfavorable outcome continued to be highly significant for all three MRI imaging time points (row 7). ConclusionsTableOptimal SI threshold value to classify unfavorable tumor voxels at different imaging timesLocal tumor controlDisease-specific survivalMRI time pointPre-RT20–25 Gy40–50 GyPre-RT20–25 Gy40–50 GyMaximum area under ROC curve (AUC)0.660.780.800.660.710.69First derivative of AUC000000Optimal SI2.12.02.11.82.11.8p value with time-specific SI0.038.0E−53.7E−50.0090.0010.003p value with same SI = 2.1 for all times0.031.2E−43.7E−50.0150.0010.008 Open table in a new tab

Characterizing Tumor Heterogeneity with Functional Imaging and Quantifying High-Risk Tumor Volume for Early Prediction of Treatment Outcome: Cervical Cancer As a Model

Therapy Outcome Prediction of Cervical Cancer with the Regression Rate of Physiologic High-risk Tumor Subvolume Assessed by DCE MRI

Tumor radiomic heterogeneity: Multiparametric functional imaging to characterize variability and predict response following cervical cancer radiation therapy.

Characterizing At-Risk Voxels by Using Perfusion Magnetic Resonance Imaging for Cervical Cancer During Radiotherapy.

Validation of Optimal DCE-MRI Perfusion Threshold to Classify At-Risk Tumor Imaging Voxels in Heterogeneous Cervical Cancer for Outcome Prediction.

Low-perfusion Tumor Subvolumes, Assessed by the Heterogeneity Functional Risk Volume Method, and Treatment Outcome in Cervical Cancer: Does Hemoglobin Matter?

Early Prediction of Treatment Outcome: Functional MR Imaging and Standard Clinical Prognostic Factors in Advanced Cervical Cancer

MRI-based Quantification of Intratumoral Heterogeneity for Predicting Treatment Response to Neoadjuvant Chemotherapy in Breast Cancer

The 4th Dimension of Tumor Volume: Dynamic Volumetric Tumor Regression Analysis in Cervical Cancer and Radiation Therapy Outcome

Microcirculatory Fraction (MCF(I)) As a Potential Imaging Marker for Tumor Heterogeneity in Breast Cancer.

MRI-guided dynamic risk assessment in cervical cancer based on tumor hypoxia at diagnosis and volume response at brachytherapy

Radiomics of Tumor Heterogeneity in Longitudinal Dynamic Contrast-Enhanced Magnetic Resonance Imaging for Predicting Response to Neoadjuvant Chemotherapy in Breast Cancer

Prognostic Value of Early Changes in Metabolic Tumor Heterogeneity for Patients with Locally Advanced Non-Small Cell Lung Cancer

Abstract 5980: Identification of pre-treatment tumor habitats for the prediction of neoadjuvant therapy response in triple negative breast cancer

Optimal Classification to Characterize Tumor Heterogeneity and At-risk Tumor Voxels by DCE MRI for Early Prediction of Therapy Outcome

Intratumoral Spatial Heterogeneity at Perfusion MR Imaging Predicts Recurrence-free Survival in Locally Advanced Breast Cancer Treated with Neoadjuvant Chemotherapy

Prediction of Early Response to Concurrent Chemoradiotherapy in Cervical Cancer: Value of Multi-Parameter MRI Combined with Clinical Prognostic Factors.

Prognostic Value of Tumor Parameters Measured by MRI in Cervical Cancer Patients Receiving CCRT.

[F18]FDG PET/CT-Derived Metabolic and Volumetric Biomarkers Can Predict Response to Treatment in Locally Advanced Cervical Cancer Patients

Quantifying Tumor Heterogeneity via MRI Habitats to Characterize Microenvironmental Alterations in HER2+ Breast Cancer

Parametric response mapping of co-registered intravoxel incoherent motion magnetic resonance imaging and positron emission tomography in locally advanced cervical cancer undergoing concurrent chemoradiation therapy